TradeLink Capital’s Biogen BIIB Stock Holding History

TradeLink Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-2,800	Closed	-$603K	–	245
2013 Q2	$603K	Buy	+2,800	New	+$598K	0.19%	92

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TradeLink Capital's BIIB Position: Q3 2013 in Review

TradeLink Capital sold out of Biogen (BIIB) in Q3 2013, closing a stake of 2,800 shares — an estimated $603K sold.

TradeLink Capital first reported a position in BIIB in Q2 2013 and held it in 1 quarter. The position peaked at $603K in Q2 2013. 656 funds tracked by Wall St. Rank hold BIIB as of Q3 2013.

TradeLink Capital reported no remaining Biogen position as of Q3 2013 after selling out during the quarter.
TradeLink Capital sold 2,800 Biogen shares in Q3 2013, an estimated $603K.
TradeLink Capital first reported a position in Biogen in Q2 2013 and held it in 1 quarter.
TradeLink Capital's Biogen position peaked at $603K in Q2 2013.
656 funds tracked by Wall St. Rank held Biogen as of Q3 2013.

Based on TradeLink Capital's 13F filing for Q3 2013, filed 12 Nov 2013.